Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk

Diabetes Care

Volumn 33, Issue 2, 2010, Pages 258-263

  Cleveringa, Frits G W ^a   Welsing, Paco M J ^a   Van Den Donk, Maureen ^a   Gorter, Kees J ^a   Niessen, Louis W ^b,c,d   Rutten, Guy E H M ^a   Redekop, William K ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; MALE; PATIENT CARE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE;

AGED; AMPUTATION; ANGINA PECTORIS; CLUSTER ANALYSIS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; LIFE EXPECTANCY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; QUALITY OF LIFE; RISK FACTORS; THERAPY, COMPUTER-ASSISTED;

EID: 75149145124     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-1232     Document Type: Article

References (25)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-932
2. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 2002; 45:S5-S12
3. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-1576
4. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-125
5. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772
6. Cleveringa FG, Gorter KJ, van den Donk M, Rutten GEHM. Combined task delegation, computerized decision support, and feedback improve cardiovascular risk for type 2 diabetic patients: a cluster randomized trial in primary care. Diabetes Care 2008;31:2273-2275
7. Bu D, Pan E, Walker J, Adler-Milstein J, Kendrick D, Hook JM, Cusack CM, Bates DW, Middleton B. Benefits of information technology-enabled diabetes management. Diabetes Care 2007;30:1137-1142
8. Ofman JJ, Badamgarav E, Henning JM, Knight K, Gano AD Jr, Levan RK, Gur-Arie S, Richards MS, Hasselblad V, Weingarten SR. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med 2004;117:182-192
9. Rutten GEHM, de Grauw WJC, Nijpels G, Goudswaard AN, Uitewaal PJM, Van der Does FEE, Heune RJ, Van Ballegooie E, Verduijn MM, Bouma M. NHG-standard diabetes mellitus type 2 (tweede herziening). Huisarts Wet 2006;49:137-152
10. Dijkstra RF, Niessen LW, Braspenning JC, Adang E, Grol RT. Patient-centred and professional-directed implementation strategies for diabetes guidelines: a cluster-randomized trial-based cost-effectiveness analysis. Diabet Med 2006;23:164 -170
11. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M. Model of complications of NIDDM. II: Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20: 735-744
12. Niessen LW, Dijkstra R, Hutubessy R, Rutten GE, Casparie AF. Lifetime health effects and costs of diabetes treatment. Neth J Med 2003;61:355-364
13. Niessen LW. Roads to Health: Multi Stage Modelling of Population Health and Resource Use. Amsterdam, the Netherlands, Dutch University Press, 2002
14. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002; 25:458-463
15. Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, Turner R. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41): United Kingdom Prospective Diabetes Study Group. BMJ 2000;320:1373-1378
16. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-679
17. Briggs A, Mihaylova B, Sculpher M, Hall A, Wolstenholme J, Simoons M, Deckers J, Ferrari R, Remme WJ, Bertrand M, Fox K. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart 2007;93:1081-1086
18. Johns B, Baltussen R, Hutubessy R. Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc 2003;1:1
19. Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005;331:446-448
20. Guidelines for pharmacoeconomic research, updated version [article online], 2006. College voor zorgverzekeringen, Diemen. Available at www.cvz.nl/ resources/FEO-guidelines%20-%20 versie%202006-tcm28-25379.pdf. Accessed 1 January 2008
21. Stolk EA, van DG, Brouwer WB, Busschbach JJ. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall. Pharmacoeconomics 2004;22:1097-1107
22. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 Study. Diabetes Care 2008;31:1510-1515
23. Del PS. Megatrials in type 2 diabetes: from excitement to frustration? Diabetologia 2009;52:1219-1226
24. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
25. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572